IBRX Stock - ImmunityBio, Inc.
Unlock GoAI Insights for IBRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14.74M | $622,000 | $240,000 | $934,000 | $605,000 |
| Gross Profit | $14.74M | $622,000 | $240,000 | $934,000 | $605,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-344,182,000 | $-362,250,000 | $-351,298,000 | $-330,280,000 | $-220,880,000 |
| Net Income | $-413,564,000 | $-583,196,000 | $-416,567,000 | $-346,790,000 | $-221,851,000 |
| Net Margin | -2804.8% | -93761.4% | -173569.6% | -37129.6% | -36669.6% |
| EPS | $-0.59 | $-1.15 | $-1.04 | $-0.89 | $-0.59 |
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Visit WebsiteEarnings History & Surprises
IBRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2025 | May 12, 2025 | $-0.12 | $-0.15 | -25.0% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.26 | $-0.15 | +42.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.17 | $-0.20 | -17.6% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.16 | $-0.20 | -25.0% | ✗ MISS |
Q1 2024 | Mar 19, 2024 | $-0.18 | $-0.19 | -5.6% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.27 | $-0.19 | +29.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.26 | $-0.28 | -7.7% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.27 | $-0.27 | 0.0% | = MET |
Q1 2023 | Mar 1, 2023 | $-0.22 | $-0.27 | -22.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.23 | $-0.28 | -21.7% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.24 | $-0.24 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $-0.22 | $-0.26 | -18.2% | ✗ MISS |
Q1 2022 | Mar 2, 2022 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.20 | $-0.22 | -10.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.12 | $-0.23 | -91.7% | ✗ MISS |
Latest News
Frequently Asked Questions about IBRX
What is IBRX's current stock price?
What is the analyst price target for IBRX?
What sector is ImmunityBio, Inc. in?
What is IBRX's market cap?
Does IBRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IBRX for comparison